Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The only visible change is the footer revision updated from v3.4.0 to v3.4.1, and the main content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-06T12:06:04.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The label in the Study Dates section changed from 'Last Update Posted (Estimated)' to 'Last Update Posted' to clarify the timestamp shown.
    Difference
    0.1%
    Check dated 2026-01-22T06:10:05.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    Revision history shows the addition of Revision: v3.3.4 and the removal of Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T03:43:12.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    A dedicated Locations section now lists Pennsylvania as the study site, replacing the prior Pennsylvania Locations entry. The footer's HHS Vulnerability Disclosure was removed and the revision updated to v3.3.3.
    Difference
    0.3%
    Check dated 2025-12-24T15:35:41.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    Revision tag updated from v3.2.0 to v3.3.2; no study information or eligibility details appear to be altered.
    Difference
    0.1%
    Check dated 2025-11-25T21:27:48.000Z thumbnail image
  7. Check
    80 days ago
    Change Detected
    Summary
    The funding and operating status banner was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-18T19:06:21.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.